Physician profile
Delfin Valite
NPI 1295794428
$14,395.91
in general payments reported to CMS, 2019-2025
35 companies · $2,840 in 2025
The $2,840 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,646 · 2020: $1,113 · 2021: $2,053 · 2022: $1,971 · 2023: $2,194 · 2024: $2,579 · 2025: $2,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,484 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,484.15 |
| Education | $128.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,820.30 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,712.95 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,279.14 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $1,265.28 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $948.57 | 2019-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $813.50 | 2019-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $779.56 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $731.78 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Neos Therapeutics, Lp | $576.32 | 2019-2025 | Adzenys Xr-Odt, Exxua, Cotempla Xr-Odt |
| Sunovion Pharmaceuticals INC. | $560.44 | 2019-2022 | |
| Lundbeck LLC | $479.41 | 2019-2024 | Rexulti |
| Axsome Therapeutics, INC. | $406.64 | 2023-2025 | Auvelity |
| Tris Pharma INC | $371.58 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| E.R. Squibb & Sons, L.L.C. | $361.82 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $264.78 | 2021-2024 | Qelbree, Qelbree |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $242.62 | 2019-2021 | |
| Allergan, INC. | $237.96 | 2019-2020 | |
| Noven Therapeutics, LLC | $212.40 | 2023-2025 | Xelstrym, Secuado |
| Indivior INC. | $161.59 | 2021-2025 | Perseris, Sublocade |
| Eisai INC. | $160.08 | 2021-2022 | |
| Corium, LLC | $119.61 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $112.92 | 2020-2025 | Fanapt, Hetlioz |
| Shire North American Group INC | $107.27 | 2019 | |
| Idorsia Pharmaceuticals US INC | $98.06 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $97.63 | 2022-2023 | Belsomra |
| Alkermes, INC. | $90.41 | 2023-2025 | Lybalvi, Aristada |
| Arbor Pharmaceuticals, INC. | $85.16 | 2019 | |
| Almatica Pharma LLC | $70.89 | 2022-2025 | Loreev Xr |
| Adlon Therapeutics L.P. | $59.90 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $38.49 | 2025 | Jornay Pm |
| Viiv Healthcare Company | $34.57 | 2025 | Dovato |
| Acadia Pharmaceuticals INC | $31.73 | 2025 | Nuplazid |
| Sage Therapeutics, LLC | $24.26 | 2023 | |
| Jazz Pharmaceuticals INC. | $19.97 | 2019 | |
| Neuronetics, INC. | $18.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delfin Valite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.